Ovarian volume data sources.

<p>The year column refers to the year of publication; * denotes our own unpublished data.</p

Model validation analysis.

<p>The tradeoff between overfit and underfit for one of the five cross-validation data splits. Models with degree less than 11 are unsuitable due to low ; models with degree greater than 17 are unsuitable due to larger differences between test and training mean-squared errors. The degree 14 model is optimal.</p

Ovarian volumes by age.

<p>Normative values for ovarian volumes in millilitres for ages from birth through 50 years at two year stages. SD below and above refer to standard deviations below and above mean predicted volume.</p

The normative validated model of ovarian volume throughout life.

<p>The red line is predicted mean ovarian volume in millilitres for any age. Colour bands indicate ranges within standard deviation from mean, within and standard deviations, and outside standard deviations.</p

Model residuals for ages up to 10 years.

<p>Residuals are the squared differences between data values and predicted values for that age.</p

Coefficients for the validated model.

<p>Coefficients for the validated normative model of human ovarian volume throughout life. Each coefficient value is reported together with estimates of the standard error, T-statistic and 95% confidence limits for the value.</p

Residual distribution for the validated model.

<p>Residuals are the squared differences between data values and predicted values for that age.</p

Model residuals for ages between 10 and 30 years.

<p>Residuals are the squared differences between data values and predicted values for that age.</p

Supplementary Material for: Thrombolysis for acute wake-up and unclear onset strokes with alteplase at 0.6 mg/kg in clinical practice: THAWS2 Study

Introduction: The aim of this study was to determine the safety and efficacy of intravenous (IV) alteplase at 0.6 mg/kg for patients with acute wake-up or unclear onset strokes in clinical practice. Methods: This multicenter observational study enrolled acute ischemic stroke patients with last-known-well time >4.5 h who had mismatch between DWI and FLAIR and were treated with IV alteplase. The safety outcomes were symptomatic intracranial hemorrhage (sICH) after thrombolysis, all-cause deaths and all adverse events. The efficacy outcomes were favorable outcome defined as an mRS score of 0–1 or recovery to the same mRS score as the premorbid score, complete independence defined as an mRS score of 0–1 at 90 days, and change in NIHSS at 24 h from baseline. Results: Sixty-six patients (35 females; mean age, 74±11 years; premorbid complete independence, 54 [82%]; median NIHSS on admission, 11) were enrolled at 15 hospitals. Two patients (3%) had sICH. Median NIHSS changed from 11 (IQR, 6.75–16.25) at baseline to 5 (3–12.25) at 24 h after alteplase initiation (change, –4.8±8.1). At discharge, 31 patients (47%) had favorable outcome and 29 (44%) had complete independence. None died within 90 days. Twenty-three (35%) also underwent mechanical thrombectomy (no sICH, NIHSS change of –8.5±7.3), of whom 11 (48%) were completely independent at discharge. Conclusions: In real-world clinical practice, IV alteplase for unclear onset stroke patients with DWI-FLAIR mismatch provided safe and efficacious outcomes comparable to those in previous trials. Additional mechanical thrombectomy was performed safely in them